Frederick L. Locke

Research interests

Publications

• A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

  Nature Medicine · 2023 · 10.1038/s41591-023-02234-6

• Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2301665

• 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

  Blood · 2023 · 10.1182/blood.2022018893

• Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

  Journal of Clinical Oncology · 2023 · 10.1200/jco.22.01365

• Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

  Nature Medicine · 2022 · 10.1038/s41591-022-01916-x

• Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

  Journal of Clinical Oncology · 2022 · 10.1200/jco.21.02370

• The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

  Journal for ImmunoTherapy of Cancer · 2022 · 10.1136/jitc-2021-004475

• Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

  Blood · 2021 · 10.1182/blood.2020007445

• Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2116133

• CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

  Blood · 2021 · 10.1182/blood.2020010543

• Efficacy and safety of CD19 ‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET , ZUMA ‐1, and TRANSCEND trials

  American Journal of Hematology · 2021 · 10.1002/ajh.26301

• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1914347

• Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.02104

• Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

  Blood Advances · 2020 · 10.1182/bloodadvances.2020002394

• Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

  Blood Advances · 2020 · 10.1182/bloodadvances.2020003092

• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

  Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2020-001511

• Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

  Haematologica · 2020 · 10.3324/haematol.2019.238634

• High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

  Blood Advances · 2020 · 10.1182/bloodadvances.2020001900

• Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

  Journal of the American College of Cardiology · 2019 · 10.1016/j.jacc.2019.10.038

• Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2019 · 10.6004/jnccn.2019.0013

• Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30864-7

• ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

  Transplantation and Cellular Therapy · 2018 · https://doi.org/10.1016/j.bbmt.2018.12.758

• Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707447

• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  Molecular Therapy · 2017 · 10.1016/j.ymthe.2016.10.020

• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  Nature Reviews Clinical Oncology · 2017 · https://doi.org/10.1038/nrclinonc.2017.148

• Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

  Blood · 2017 · https://doi.org/10.1182/blood.v130.suppl_1.1547.1547

Current projects

No projects listed.